£36.00
Additional information
| Active substance | Thalidomide |
|---|---|
| Water Retention | No significant water retention |
| Hepatotoxicity | Low risk of hepatotoxicity |
| Lab Test | Not specifically required for monitoring thalidomide itself but monitoring of complete blood counts and liver function tests are advised during treatment |
| Strength | 50mg |
| Also known as | N/A |
| Blood pressure | No specific impact on blood pressure |
| Trade name | Thalomid |
| Storage conditions | Store at room temperature away from moisture and heat |
| Chemical name | (RS)-2-(2,6-Dioxopiperidin-3-yl)isoindoline-1,3-dione |
| Formula | C13H10N2O4 |
| Substance class | Immunomodulatory drug |
| Main action | Immunomodulatory and anti-inflammatory effects |
| Half-life | 5 to 7 hours |
| Dosage (medical) | Typically 100 to 300 mg per day, depending on the condition being treated |
| Dosage (sports) | Not applicable |
| Effects | Reduction of inflammation, modulation of immune response |
| Side effects | Teratogenicity (causes birth defects), peripheral neuropathy, deep vein thrombosis, risk of severe life-threatening human birth defects |
| Use in sports | None |
| Manufacturer | Natco Pharmaceuticals Ltd. |
| Packing | 10 caps/blister |
